TABLE 5.
Outcomes of the study
| Outcome | Value(s) [means ± SD or n (%)] |
P value | |
|---|---|---|---|
| IFN group (n = 42) | Control group (n = 39) | ||
| Time from starting the interventions to the clinical response (days) | 9.74 ± 5.8 | 8.39 ± 4.9 | 0.95 |
| Required invasive mechanical ventilation | 15 (35.71) | 17 (43.58) | 0.30 |
| Extubation ratec (%) | 8 (53.33) | 2 (11.76) | 0.019 |
| Duration of mechanical ventilation (days) | 10.86 ± 5.38 | 7.82 ± 7.84 | 0.47 |
| Duration of ICU stay (days) | 7.71 ± 8.75 | 8.52 ± 7.48 | 0.42 |
| Duration of hospital stay (days) | 14.80 ± 8.45 | 12.25 ± 7.48 | 0.69 |
| Death in hospital | 8 (19.04) | 16 (41.02) | 0.027 |
| Death in general wardsa | 0 | 2 (12.50) | 0.17 |
| Death in ICUb | 8 (42.10) | 14 (60.86) | 0.14 |
| 28-Day mortality | 8 (19) | 17 (43.6) | 0.015 |
| Complications | |||
| Acute kidney injury | 12 (28.57) | 11 (28.20) | 0.58 |
| Nosocomial infections | 11 (26.19) | 5 (12.82) | 0.09 |
| Septic shock | 10 (23.80) | 7 (17.94) | 0.35 |
| Hepatic failure | 5 (11.90) | 9 (23.07) | 0.15 |
| Deep vein thrombosis/pulmonary thromboembolism | 1 (2.38) | 0 | 0.51 |
| Adverse events | |||
| Hypersensitivity reactions | 1 (2.38) | 0 | 0.51 |
| IFN-related injection reactions | 8 (19.04) | 0 | |
| Neuropsychiatric problems | 4 (9.52) | 0 | 0.06 |
| Indirect hyperbilirubinemia | 1 (2.38) | 1 (2.56) | 0.73 |
a
Twenty-two patients in the IFN group and 16 patients in the control group were in the general ward.
b
Nineteen patients in the IFN group and 23 patients in the control group were in the intensive critical unit.
c
The percentage of extubated patients was calculated according to the number of intubated patients.